Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’
Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages…
Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’
Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy. The post Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’ appeared first on…
How Knowtex Landed an AI Scribe Contract With the VA
CEO Caroline Zhang says that after winning an AI tech sprint, Knowtex is already in 310 clinics and 79 hospitals in the VA
It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreements
For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ensure continued compliance. The post It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreements appeared first on MedCity News.
A Meaningful Signal on Palliative Care – But Not Yet a Benefit
CMS asked the right questions – the ones that will determine whether any future benefit actually reaches these patients. The post A Meaningful Signal on Palliative Care – But Not Yet a Benefit appeared first on MedCity News.
Medicare Drug Plans Are Hiking Premiums While Trump Claims Victory on Medicine Prices
Millions of Medicare enrollees who buy stand-alone prescription drug plans will see their average monthly premiums rise by 50% in 2027, a new analysis finds. But enrollees can avoid the average increase — from $34 a month to $51 — by switching to lower-cost plans during the program’s open enrollment period, which runs through Dec….
For Californians Drowning in Healthcare Costs, Governor’s Race Offers Few Answers
When Ashley Porter began slurring her speech one October day four years ago, doctors suspected a stroke. A spinal tap, an MRI, dozens of blood draws, another MRI, and a night spent at the hospital were followed, finally, by an answer: Porter had multiple sclerosis. Her shock turned to outrage, she said, when she received…
Your Phone Knows You’re at the Doctor, and Data Brokers Do, Too — Then Profit From It
Chris McQueen finished treatment for leukemia a year and a half ago, but the ads for fake cures never stopped. Juice cleanses to cure cancer, “natural” cancer treatments, clinics in Mexico promising full recovery with little chemotherapy — all appeared on McQueen’s mobile phone during routine oncologist visits and monthly bloodwork. McQueen and others have…
Frights, Fangs, and Healthcare Nightmares in Winning Halloween Haikus
What’s scarier than ghosts and goblins? How about measles, unaffordable dental care, and an insurance claim denied by artificial intelligence? Nearly 80 healthcare-themed haikus crept into our inbox this Halloween season. Meet the winners of KFF Health News’ eighth annual Halloween haiku contest below. Follow KFF Health News’ social media accounts (X, Instagram, and Facebook)…
Medicare Part D Premiums and Cost Sharing in 2027
Medicare Part D is a voluntary outpatient prescription drug benefit for people with Medicare provided through private plans, including stand-alone prescription drug plans and Medicare Advantage plans that offer drug coverage. This analysis provides an overview of Medicare Part D premiums and cost sharing in 2027 and key trends over time.
The Average Monthly Premium for Medicare Part D Stand-Alone Plans Is Projected to Increase by 50% From $34 to $51 in 2027 Unless Enrollees Switch to Lower-Cost Plans
A new KFF analysis finds that the average monthly premium for Medicare Part D coverage in stand-alone prescription drug plans (PDPs) will increase to $51 in 2027, up 50% from $34 in 2026, if current enrollees don’t switch into lower-premium plans during open enrollment, which runs through December 7.
